Myeloproliferative neoplasms represent a heterogenous group of disorders of the
hematopoietic stem cell, with an intrinsic risk of evolution into acute myeloid leukemia. The …

Introduction: The incidence of acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS) is increasing with the aging population. Prognosis and overall survival …

Abstract Objective To document the Mayo Clinic decades-long experience with
myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and …

Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic
myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia …

Secondary AML (sAML), referring to AML arising after prior cytotoxic/radiation/
immunosuppressive therapy (tAML) or an antecedent hematologic disorder, now primarily …

Abstract Myeloproliferative Neoplasms (MPNs) are a group of progressive diseases that
share a common pathogenesis, clinical and laboratory features, as well as a spontaneous …

Abstract Objective Approximately 10% of Philadelphia (Ph)‐negative myeloproliferative
neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this …

There have been some reports on a possible role of azacytidine (AZA) in the treatment of
accelerated/blastic phase evolved from Philadelphia‐negative myeloproliferative neoplasms …

The BCR-ABL1–negative myeloproliferative neoplasms (MPNs), including polycythemia
vera, essential thrombocythemia, and primary myelofibrosis, can evolve into a form of …

JAK2 mutations are rare in de novo acute myeloid leukemia (AML), and JAK2-mutated acute
myeloid leukemia (AML) patients usually have a previous history of myeloproliferative …